利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.042 秒)

    ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER
    4.
    发明申请
    ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER 审中-公开
    抗CD151抗体及其在治疗癌症中的应用

    公开(公告)号：US20120171114A1

    公开(公告)日：2012-07-05

    申请号：US13306839

    申请日：2011-11-29

    申请人： Jean-François Haeuw

    发明人： Jean-François Haeuw

    IPC分类号： A61K39/395 ,  C12N5/18 ,  C12N15/13 ,  C12N15/63 ,  C12N1/19 ,  C12P21/02 ,  A61K51/00 ,  G01N33/566 ,  C12N5/10 ,  C12N1/21 ,  C07K16/28 ,  A01K67/027

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565

    摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人CD151蛋白，特别是鼠来源的单克隆抗体，它们是嵌合和人源化的新抗体，以及编码这些抗体的氨基酸和核酸序列。 本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。 最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

    Anti-CD151 antibodies and their use in the treatment of cancer
    5.
    发明授权
    Anti-CD151 antibodies and their use in the treatment of cancer 失效
    抗CD151抗体及其在治疗癌症中的应用

    公开(公告)号：US08697855B2

    公开(公告)日：2014-04-15

    申请号：US13440259

    申请日：2012-04-05

    申请人： Jean-François Haeuw

    发明人： Jean-François Haeuw

    IPC分类号： C07H21/00

    CPC分类号： C07K16/30 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565

    摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanized, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人CD151蛋白的新型抗体，特别是嵌合和人源化的鼠来源的单克隆抗体，以及编码这些抗体的氨基酸和核酸序列。 本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。 最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

    CHIMERIC ANTIBODIES SPECIFIC FOR CD151 AND USE THEREOF IN THE TREATMENT OF CANCER
    6.
    发明申请
    CHIMERIC ANTIBODIES SPECIFIC FOR CD151 AND USE THEREOF IN THE TREATMENT OF CANCER 审中-公开
    CD151特异性抗体特异性及其在治疗癌症中的应用

    公开(公告)号：US20120275997A1

    公开(公告)日：2012-11-01

    申请号：US13500745

    申请日：2010-10-08

    申请人： Jean-François Haeuw

    发明人： Jean-François Haeuw

    IPC分类号： A61K39/395 ,  C12N15/13 ,  A61P35/00 ,  C12N5/10 ,  A01K67/00 ,  A61K51/00 ,  C07K16/18 ,  C12N15/85

    CPC分类号： C07K16/2896 ,  C07K2317/24

    摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those anitbodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人CD151蛋白的新型抗体，特别是嵌合和人源化的鼠来源的单克隆抗体，以及编码这些抗体的氨基酸和核酸序列。 本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。 最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

    Anti-IGF-IR antibodies and uses thereof
    7.
    发明授权
    Anti-IGF-IR antibodies and uses thereof 有权
    抗IGF-1R抗体及其用途

    公开(公告)号：US08168410B2

    公开(公告)日：2012-05-01

    申请号：US13037734

    申请日：2011-03-01

    申请人： Liliane Goetsch ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    发明人： Liliane Goetsch ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    IPC分类号： C12P19/34 ,  C12N15/00 ,  C12N15/13 ,  C07H21/04 ,  C07K16/28

    CPC分类号： A61K47/6805 ,  C07K2317/732 ,  Y10S425/81

    摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的这些抗体及其用于预防和/或治疗某些癌症的用途的产品和/或组合物。

    Anti-CD151 antibodies and their use in the treatment of cancer
    8.
    发明授权
    Anti-CD151 antibodies and their use in the treatment of cancer 失效
    抗CD151抗体及其在治疗癌症中的应用

    公开(公告)号：US08198413B2

    公开(公告)日：2012-06-12

    申请号：US12576824

    申请日：2009-10-09

    申请人： Jean-François Haeuw

    发明人： Jean-François Haeuw

    IPC分类号： C12P21/06

    CPC分类号： C07K16/30 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565

    摘要： The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人CD151蛋白，特别是鼠来源的单克隆抗体，它们是嵌合和人源化的新抗体，以及编码这些抗体的氨基酸和核酸序列。 本发明还包括使用那些抗体作为用于预防和/或治疗癌症的药物以及用于与CD151蛋白过量表达相关的疾病的诊断方法或试剂盒。 最后，本发明包括与抗体和/或抗癌剂相关联的包含这种抗体或与毒素和/或放射性元素缀合的这些抗体及其在预防和/或治疗某些癌症中的用途的产品和/或组合物。

    NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF
    9.
    发明申请
    NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF 有权
    新型抗IGF-1R抗体及其用途

    公开(公告)号：US20110183376A1

    公开(公告)日：2011-07-28

    申请号：US13037734

    申请日：2011-03-01

    申请人： Liliane GOETSCH ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    发明人： Liliane GOETSCH ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    IPC分类号： C12P21/04 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10

    CPC分类号： A61K47/6805 ,  C07K2317/732 ,  Y10S425/81

    摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

    Anti-IGF-IR antibodies and uses thereof
    10.
    发明授权
    Anti-IGF-IR antibodies and uses thereof 有权
    抗IGF-1R抗体及其用途

    公开(公告)号：US07241444B2

    公开(公告)日：2007-07-10

    申请号：US10735916

    申请日：2003-12-16

    申请人： Liliane Goetsch ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    发明人： Liliane Goetsch ,  Nathalie Corvaia ,  Olivier Leger ,  Alain Duflos ,  Jean-François Haeuw ,  Alain Beck

    IPC分类号： C07K16/28 ,  C12P21/08 ,  A61K39/395 ,  A61K39/00 ,  G01N33/53

    CPC分类号： A61K47/6805 ,  C07K2317/732 ,  Y10S425/81

    摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

    摘要翻译： 本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体， 人源化，以及编码这些抗体的氨基酸和核酸序列。 本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。 本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。